Abstract
BackgroundEphAs are a class of ephrin receptors that belong to the membrane-bound receptor tyrosine kinases group. Accumulating experimental evidence has shown that the EphA family is involved in tumor progression, namely in cell proliferation, invasiveness, and metastasis. EphAs are a promising target for anticancer therapy. However, their role in breast cancer (BC) is still not well understood.Materials and MethodsWe used a series of bioinformatic approaches to analyze the expression of the EphA family members and investigate their prognostic value in BC.ResultsLower expression levels of EphA2, EphA3, EphA4, EphA5, and EphA7 and higher expression levels of EphA10 were found in BC tissues compared to those in normal tissues. The expression levels of the EphA family genes were correlated with molecular subtyping but not with tumor stage. High expression levels of most EphAs indicated a better prognosis in BC.ConclusionsThis study suggested that EphA2, EphA3, EphA4, and EphA5 can act as tumor-inhibiting factors as well as biomarkers for the prognosis of BC.
Highlights
Each year, worldwide, there are an estimated 1.5 million new cases of breast cancer (BC), which is one of the most frequently diagnosed malignancies in women [1]
The results showed that the expression levels of EphA2, EphA3, EphA4, EphA5, EphA7, and EphA8 were reduced, but the expression levels of EphA1 and EphA10 were significantly increased in BC tissues (P < 0.01)
The results indicated that the expression levels of EphA2, EphA3, EphA4, EphA5, EphA6, and EphA7 were significantly lower in BC tissues than in normal tissues, and the expression levels of EphA8 and EphA10 were significantly higher in BC tissues
Summary
Worldwide, there are an estimated 1.5 million new cases of breast cancer (BC), which is one of the most frequently diagnosed malignancies in women [1]. The strategies for the treatment of BC include surgery, radiation, traditional chemotherapy, endocrine therapy, and targeted therapy. These treatments have greatly improved the progression-free and overall survival of patients with BC. The knowledge on these BC subtypes can be used for clinical decision making to improve the rate of survival for BC. The major reason for this is the high recurrence and metastasis rates in patients with BC. The 5-year survival rate for BC is still less than 20%. EphAs are a promising target for anticancer therapy. Their role in breast cancer (BC) is still not well understood
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
